705-80-6

Basic information

• Product Name: Acetamide, N-(3-fluoro-4-iodophenyl)-
• CAS NO: 705-80-6
• Molecular Formula: C8H7FINO
• Molecular Weight: 279.053
• Mol File: 705-80-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Acetamide, N-(3-fluoro-4-iodophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-(3-fluoro-4-iodophenyl)-(705-80-6)
• EPA Substance Registry System: Acetamide, N-(3-fluoro-4-iodophenyl)-(705-80-6)

Safety Data

• Hazardous Substances Data: 705-80-6(Hazardous Substances Data)

Upstream product

• 656-66-6 3-fluoro-4-iodoaniline 
• 108-24-7 acetic anhydride 
• 372-19-0 meta-fluoroaniline 
• 351-28-0 N-(3-fluorophenyl)acetamide 

Relevant articles and documents

Disulfide-Catalyzed Iodination of Electron-Rich Aromatic Compounds

Herein, a disulfide-catalyzed electrophilic iodination of aromatic compounds using 1,3-diiodo-5,5-dimethylhydantoin (DIH) has been developed. The disulfide activates DIH as a Lewis base to promote the iodination reaction in acetonitrile under mild conditions. This system is applicable to a wide range of electron-rich aromatic compounds, including acetanilide, anisole, imidazole, and pyrazole derivatives.

Halogenated antituberculosis agents

Halogenated derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized. In general, the halogenated compound has the structure of Structure I: wherein X1is a halogen and X2is a second halogen or hydrogen, and Y is sulfur or oxygen; or, has the structure of Structure IV: wherein X1is a halogen and X2is a second halogen or hydrogen. Alternatively, the halogenated compounds may be pharmaceutically acceptable salts of these compounds. These halogenated derivatives possess anti-mycobacterial activity and are particularly useful for the treatment of Mycobacterium tuberculosis infections. In particular, fluorinated analogs of thioacetazone and p-amino-salicylic acid have been synthesized for use as anti-tuberculosis therapeutic agents either alone or in combination with other conventional anti-tuberculosis therapeutic agents.